Pigmentation Control

Description

The Pigmentation Control Research Kit combines PT-141 (Bremelanotide, 10mg) and Thymalin (10mg) — addressing melanocortin receptor biology (PT-141) and thymic immune bioregulator activity (Thymalin) within a single research kit designed for melanocortin system and thymic peptide interaction studies.

Kit Components

• PT-141 / Bremelanotide (10mg): Cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R selective). Derived from Melanotan II. Activates melanocortin pathways in the hypothalamus. FDA-approved compound (Vyleesi) providing extensive clinical pharmacological reference data.
• Thymalin (10mg): Thymic polypeptide bioregulator (Khavinson cytomedine class) studied for T-lymphocyte activity modulation, immune homeostasis, and neuroendocrine-immune axis regulation. Frequently studied alongside melanocortin research due to shared neuroendocrine immunomodulation pathways.

Research Context

The melanocortin system (targeted by PT-141) and the thymic immune system (targeted by Thymalin) share neuroendocrine regulatory overlap through the hypothalamic-pituitary axis. Researchers investigating immunological modulation in the context of melanocortin pathway activation, or studying neuroendocrine-immune crosstalk, use these compounds together to examine pathway interactions.

Common Research Applications

• Melanocortin receptor biology and neuroendocrine-immune crosstalk
• MC3R/MC4R pharmacology with thymic immune context
• Hypothalamic-immune axis interaction research
• Thymic bioregulator + melanocortin combination studies

For Research Use Only. Not for human or veterinary use.